Incidence and Clinical, Virological, and Resistance Characteristics of HIV Infections Among pre-Exposure Prophylaxis Users in Spain (SCOPE Study): A Multicentre Prospective and Retrospective Cohort Study
Mar Vera(Hospital Clínico San Carlos), Lucía Bailón(Hospital Universitari Germans Trias i Pujol), David Rial‐Crestelo, Juan Ambrosioni(Hospital Clínic de Barcelona), Boris Revollo(Institut Català d'Oncologia), Hadrián Pernas(Galicia Sur Biomedical Foundation), Marta Rosas Cancio-Suárez(Universidad de Alcalá), Josep Mallolas(Hospital Clínic de Barcelona), Nicolás de Loredo(Hospital Clínic de Barcelona), Eva Ariza-Vioque(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Alberto Foncillas(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), César Sotomayor(Instituto de Biomedicina de Sevilla), David García Hernández, Naya Faro(Instituto de Investigación Biosanitaria de Granada), Carmen Hurtado, Haridian Tato(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Alexandre Pérez(University Hospital Complex Of Vigo), Patricia Álvarez-López(Vall d'Hebron Hospital Universitari), Montserrat Laguno, Juan Ambrosioni(Instituto de Salud Carlos III), Claudia Broto(Vall d'Hebron Hospital Universitari), Santiago Fernández-Castelao(Hospital Clínico San Carlos), Ángel Rivero(Hospital Universitari Germans Trias i Pujol), Sònia Vicens-Artés, María del Mar Arcos-Rueda(Hospital Universitario La Paz), Josep M. Llibre(Hospital Universitari Germans Trias i Pujol), Cristina Rovira, Elisa de Lazzari(Instituto de Salud Carlos III), Damian Malano, Juan Ambrosioni(Instituto de Salud Carlos III), Ana Gonzalez‐Cordón
Cited by 0
Related Papers
Monkeypox outbreak in Madrid (Spain): Clinical and virological aspects
|Journal of Infection|2022|174
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
|The Lancet Infectious Diseases|2015|143
Highlights of the 2017 European <scp>AIDS</scp> Clinical Society (EACS) Guidelines for the treatment of adult <scp>HIV</scp>‐positive persons version 9.0
|HIV Medicine|2018|138
Gut Bacteria Metabolism Impacts Immune Recovery in HIV-infected Individuals
|EBioMedicine|2016|112